Influenza
Influenza, commonly known as "the flu," is a respiratory infection caused by influenza viruses, characterized by symptoms such as fever, runny nose, sore throat, muscle pain, headache, coughing, and fatigue. While it typically resolves within a week, it can lead to severe complications in newborns, older adults, and individuals with weakened immune systems.
Health Outcomes
- Accelerated Recovery of B Cell-Mediated Respiratory Immunity
- Achieved Complete Symptom Cessation
- Altered Innate Immune Response
- Colonization of Nasopharynx or Adenoid Tissue
- Duration of Symptoms
- Enhanced Antibody Production
- Enhanced Antipathogenic Activity
- Enhanced Antiviral Response
- Enhanced Disease Resistance
- Enhanced Early Immune Response
- Enhanced Host Resistance
- Enhanced IgA Response
- Enhanced Immune Capacity
- Enhanced Immune Evasion
- Enhanced Immune Function
- Enhanced Immune Function Post-Intervention
- Enhanced Immune Memory
- Enhanced Immune Profile
- Enhanced Immune Status
- Enhanced Immune System
- Enhanced Immune System Function
- Enhanced Immunity
- Enhanced Immunological Defense Against Respiratory Viral Infections
- Enhanced Innate Antiviral Immune Response
- Enhanced Interferon Production
- Enhanced Non-specific Immune Defense
- Enhanced Peripheral Immunity
- Enhanced Phagocytic Activity of Peritoneal Macrophages
- Enhanced Phagocytosis by Monocyte-Derived Dendritic Cells
- Enhanced Protection Against Infection
- Enhanced Protection Against Influenza Infection
- Enhanced Resistance to Infections
- Enhanced Resistance to Respiratory Infections
- Enhanced Respiratory Burst Activity
- Enhanced Systemic Immune Response
- Improved Acquired Immunity
- Improved Anti-infection Response
- Improved Antiviral Effect
- Improved Antiviral Immune Response
- Improved Antiviral Response
- Improved Clinical Protection Against Viral Challenge
- Improved Clinical Symptoms of Influenza
- Improved Cure Rate
- Improved Cure Rate on Day 3
- Improved Defense Mechanism Recovery
- Improved Disease Resolution
- Improved Host Health
- Improved Host Immunity
- Improved Humoral Immune Parameters
- Improved Humoral Immune Response
- Improved Immune Function
- Improved Immune Response
- Improved Immune Surveillance
- Improved Immune System Activity
- Improved Immune System Modulation
- Improved Immunity
- Improved Immunological Biomarkers
- Improved Immunological Response
- Improved Infection Protection
- Improved Innate Immune Response
- Improved Innate Immunity
- Improved Leukocyte Recruitment
- Improved Lower Limit of Detection
- Improved Mucosal Immunity
- Improved Natural Killer Cell Function
- Improved Nonspecific Humoral Response
- Improved Overall Survival During Infection
- Improved Pathogen Tolerance
- Improved Perceived Recovery
- Improved Phagocytic Activity of Macrophages
- Improved Phagocytic Function
- Improved Phagocytosis
- Improved Recovery Rate
- Improved Relative Survival Rate Against Pathogen
- Improved Resistance against Infections
- Improved Resistance to Infections
- Improved Resistance to Pathogenic Infection
- Improved Resistance to Viral Infections
- Improved Respiratory Immunity
- Improved Respiratory Infection Resistance
- Improved Response
- Improved Seroconversion
- Improved Serum Immunity
- Improved Specific Antibody Response
- Improved Survival After Viral Challenge
- Improved Survival Rate Against Infection
- Improved Symptom Resolution
- Improved Symptom Resolution Rate
- Improved Systemic Immunity
- Improved Total Antibody Concentration
- Improved Vaccine-Specific IgG Levels
- Improved Vaccine-Specific Secretory IgA Levels in Saliva
- Increased Anti-Influenza Virus Antibodies
- Increased Antibody Levels for Avian Influenza Virus
- Increased Antibody Response
- Increased Antibody Titer
- Increased Antigen-Specific Immunoglobulin A
- Increased Body Temperature
- Increased Days Without Illness
- Increased Fever
- Increased Fever-Free Days
- Increased Granulocyte Count
- Increased IL-8 Levels at 24 Hours
- Increased Immune Function
- Increased Incidence of Upper Respiratory Tract Infections
- Increased Infection
- Increased Interferon Production
- Increased Mucosal B-Cell Responses
- Increased Natural Killer Cell Proportion
- Increased Salivary IgA Levels for Influenza A Virus H3N2
- Increased Salivary Influenza Virus-Bound IgA
- Increased Secretory IgA Production
- Increased Specific Antibody Levels
- Increased Survival Against Pathogens
- Increased Survival During Pathogenic Exposure
- Increased Survival Rates of Infected Hosts
- Increased Vaccine-Specific Plasma Immunoglobulin G (IgG)
- Induced Antigen-Specific Protective Mucosal Immune Response
- Maintained Higher Salivary Immunoglobulin A Levels
- Maintenance of NK Cell Activity
- No Adverse Safety Findings
- No Antiviral Effect
- No Change in Blood-Culture Confirmed Sepsis
- No Measurable IFN-Alpha Induction
- No Significant Change in Hemagglutination Inhibition Titers
- Post-Vaccinal Immunostimulatory Effect
- Prevented Upper Respiratory Tract Infection
- Protection Against Pathogen Dissemination
- Reduced Acute Respiratory Tract Infection Incidence
- Reduced Antibiotic Usage
- Reduced Antibiotic and Antiviral Use
- Reduced Antimicrobial Use
- Reduced Bloody Nasal Mucus
- Reduced Cervical Lymphadenopathy Frequency
- Reduced Cold and Flu Incidence
- Reduced Cold/Flu Medication Use
- Reduced Cold/Flu Severity
- Reduced Community-Acquired Infection
- Reduced Cough Duration
- Reduced Cumulative Mortality After Infection
- Reduced Day Care Absence
- Reduced Day Care Absenteeism Due to Infections
- Reduced Days with Runny Nose Symptoms
- Reduced Duration of Antipyretic Therapy
- Reduced Duration of Common Cold Episodes
- Reduced Duration of Febrile Episodes
- Reduced Duration of Infectious Diseases
- Reduced Duration of Nasal Symptoms
- Reduced Duration of Respiratory Infection
- Reduced Duration of Respiratory Tract Infection Episode
- Reduced Duration of Respiratory Tract Infections
- Reduced Duration of URTI-Associated Symptoms
- Reduced Duration of Upper Respiratory Symptoms
- Reduced Duration of Upper Respiratory Tract Infection
- Reduced Episode Duration
- Reduced Febrile Flares
- Reduced Fever
- Reduced Fever Days
- Reduced Fever Duration
- Reduced Fever Duration During CID
- Reduced Fever Incidence
- Reduced Frequency of Upper Respiratory Tract Infections
- Reduced Hoarseness Duration
- Reduced Household Transmission Rate
- Reduced Illness Incidence
- Reduced Incidence of Cold/Flu Days
- Reduced Incidence of Common Cold
- Reduced Incidence of Common Infections
- Reduced Incidence of Infections
- Reduced Incidence of Influenza-like Illness
- Reduced Incidence of Upper Respiratory Tract Infections
- Reduced Infection Incidence
- Reduced Infection Rate
- Reduced Infection Severity
- Reduced Influenza Symptom Duration
- Reduced Influenza Symptoms
- Reduced Influenza Virus Titer
- Reduced Lower Respiratory Infection
- Reduced Lung Viral Proliferation
- Reduced Lung Viral Titers
- Reduced Lung Viral Titers After Influenza
- Reduced Mean Number of Infections per Child
- Reduced Mortality Post-Infection
- Reduced Mortality Rate During Pathogen Challenge
- Reduced NO Secretion Induced by LPS
- Reduced Nasal Congestion
- Reduced Nasal Symptom Score
- Reduced Otitis Media Episode Incidence
- Reduced Parental Absenteeism from Work
- Reduced Pathogen Activity
- Reduced Pathogen Attachment
- Reduced Pathogen Excretion
- Reduced Pathogen Growth
- Reduced Pathogen Incidence
- Reduced Pathogen-Induced Weight Loss
- Reduced Pharyngitis/Tonsillitis Incidence
- Reduced Postinfective Symptoms
- Reduced Recovery Time
- Reduced Respiratory Infections in Infants
- Reduced Respiratory Pathogen Load
- Reduced Respiratory Symptoms
- Reduced Respiratory Tract Infection
- Reduced Respiratory Tract Infection Episode
- Reduced Respiratory Tract Infection Episodes
- Reduced Respiratory Tract Infections
- Reduced Risk of Pathogen Dissemination
- Reduced School Absence Days
- Reduced School Absenteeism Due to Infectious Diseases
- Reduced Sepsis Incidence
- Reduced Severity of Acute Respiratory Infection
- Reduced Severity of Nasal Congestion and Runny Nose
- Reduced Severity of URTIs
- Reduced Sick Leave Days
- Reduced Sore Throat Duration
- Reduced Sore Throat Severity
- Reduced Symptom Duration
- Reduced Time to Symptom Resolution
- Reduced Total Infections
- Reduced URTI Symptoms
- Reduced Upper Respiratory Tract Infection
- Reduced Upper Respiratory Tract Infection Days
- Reduced Upper Respiratory Tract Infection Duration
- Reduced Upper Respiratory Tract Infection Severity
- Reduced Upper Respiratory Tract Infection Symptom Severity
- Reduced Upper Respiratory Tract Infection Treatment Duration
- Reduced Viral Activity
- Reduced Viral Binding
- Reduced Viral Clearance Time
- Reduced Viral Entry
- Reduced Viral Infection
- Reduced Viral Infection Incidence
- Reduced Viral Load in Epithelial Cells
- Reduced Viral Respiratory Infection
- Reduced Virulence of Pathogens
- Reduced Virulence or Safety Concerns
- Reduced Virus Titer
- Reduced Virus Titers in Bronchoalveolar Lavage Fluid
- Restored Immunological Function in Immunosuppressed Mice
- Shortened Treatment Course
- Strain Authentication and Identification
- Sustained Immune Function
- White Blood Cell Count